← Return to all swing-trade opportunities
ASND — Trend Pullback to 20 EMA
Status: Watch
Scanner score: 65.0/100
Why this was flagged
ASND was identified as a bullish technical setup based on the Trend Pullback to 20 EMA pattern. The scanner found a score of 65.0/100 using trend alignment, momentum, price action, volume, and risk-management rules.
Trade framework
Position-sizing example
These examples use the distance between the reference entry and stop-loss. They do not account for commissions, slippage, taxes, overnight gaps, or your personal account size.
Exit plan
- Stop-loss: Exit if the stop-loss is reached. Do not move the stop farther away to avoid taking the planned loss.
- Target 1: Consider taking partial profit when Target 1 is reached and reducing risk on the remaining shares.
- Target 2 or trailing exit: Consider closing the remaining position at Target 2, or use a disciplined trailing stop only if the trend remains strong.
- Time exit: Reassess or close a trade that fails to progress within the suggested holding window.
Technical chart
Daily closing price with moving averages and planned trade levels. This chart is a screening aid, not a guarantee of future results.
$1,000 educational outcome examples
These examples use a $1,000 position and fractional shares at the midpoint of the entry zone. Actual results can differ because of market gaps, fills, spreads, commissions, taxes, slippage, and changing conditions.
Easy explanation for new investors
Recent news context
This automated review is separate from the technical score. It summarizes recent related articles and does not predict price movement.
Recent-news context is being prepared. Please check back shortly.
Recent related articles
Ascendis Pharma and BioMarin Pharmaceutical Inc. have entered into a binding term sheet for a global settlement and license agreement regarding YUVIWEL® and navepegritide-related products. BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing license and waive certain regulatory rights, while Ascendis will…
Ascendis Pharma (ASND) stock rose over 7% after announcing a global settlement and license agreement with BioMarin Pharmaceutical (BMRN) concerning YUVIWEL and navepegritide products. The agreement resolves all legal disputes, with BioMarin granting Ascendis a non-exclusive license and Ascendis agreeing to pay…
Important: Some returned articles may describe competitors, industry conditions, or related companies. Open the source before relying on an article.
Scanner confirmations
- Price is above the 20-, 50-, and 200-day moving averages, with bullish moving-average alignment.
- RSI is in a constructive momentum range without being overbought.
- Price is near the 20 EMA in a bullish trend and the current candle is positive.